{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-043290","form_type":"8-K","ticker":"ICCC","cik":"0000811641","company_name":"IMMUCELL CORP /DE/","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.361509+00:00","generated_at":"2026-05-21T11:41:52.818926+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.72,"calibrated_materiality_score":0.72,"confidence":"high","headline":"ImmuCell Q1 product sales up 11% to $8.1M, net income $1.4M ($0.16 EPS) vs loss year ago","bullets":["Q1 product sales $8.1M (record high), up 11% YoY; 6-month sales $15.8M (+28%).","Net income $1.4M ($0.16 diluted EPS) vs net loss of $438K ($0.06 loss) in Q1 2024.","Gross margin improved to 42% from 32% YoY; adjusted EBITDA $2.3M for Q1.","Cash $4.6M, no draw on $1M line; working capital $12.1M, equity $29M.","Contract manufacturer issues delay Re-Tain; company exploring strategic options for the technology."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-043290","json":"https://secwatch.observer/filing/0001213900-25-043290.json","markdown":"https://secwatch.observer/filing/0001213900-25-043290.md","text":"https://secwatch.observer/filing/0001213900-25-043290.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/811641/000121390025043290/0001213900-25-043290-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/811641/000121390025043290/ea0241943-8k_immucell.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T11:41:52.818926+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}